Company Overview - TG Therapeutics was founded in 2012, focusing on B-cell-mediated diseases, including autoimmune diseases, neuroinflammatory conditions, and cancer [3] - The company is primarily focused on multiple sclerosis (MS) and has one approved drug, BRIUMVI, which is approaching blockbuster status [3] Product Information - BRIUMVI is an anti-CD20 monoclonal antibody that was approved in late December 2022 and launched in January 2023 [4] - The drug is not only available in the U.S. but has also been launched globally [4] Clinical Development - TG Therapeutics has two pivotal trials ongoing to expand the utilization and total addressable market for BRIUMVI [3] - The company has three additional programs under development [3]